Evidence map›Paper›PMID 36371541›Full record

ArticleCommunications biology2022

Development of a ternary cyclodextrin-arginine-ciprofloxacin antimicrobial complex with enhanced stability.

Marija Vukomanovic, Lea Gazvoda, Mario Kurtjak, Jitka Hrescak, Blaž Jaklic, Laura Moya-Andérico, Maria Del Mar Cendra, Eduard Torrents

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Marija VukomanovicAdvanced Materials Department, Institute Jozef Stefan, Jamova 39, Ljubljana, Slovenia. marija.vukomanovic@ijs.si.ORCID 0000-0001-7034-0471
Lea GazvodaAdvanced Materials Department, Institute Jozef Stefan, Jamova 39, Ljubljana, Slovenia.
Mario KurtjakAdvanced Materials Department, Institute Jozef Stefan, Jamova 39, Ljubljana, Slovenia.
Jitka HrescakCenter for Electronic Microscopy and Microanalysis (CEMM), Institute Jozef Stefan, Jamova 39, Ljubljana, Slovenia.
Blaž JaklicAdvanced Materials Department, Institute Jozef Stefan, Jamova 39, Ljubljana, Slovenia.
Laura Moya-AndéricoBacterial Infections: Antimicrobial Therapies, Institute for Bioengineering of Catalonia (IBEC), The Institute of Science and Technology, Baldiri Reixac 15-21, 08028, Barcelona, Spain.
Maria Del Mar CendraBacterial Infections: Antimicrobial Therapies, Institute for Bioengineering of Catalonia (IBEC), The Institute of Science and Technology, Baldiri Reixac 15-21, 08028, Barcelona, Spain.ORCID 0000-0002-2100-2406
Eduard TorrentsBacterial Infections: Antimicrobial Therapies, Institute for Bioengineering of Catalonia (IBEC), The Institute of Science and Technology, Baldiri Reixac 15-21, 08028, Barcelona, Spain. etorrents@ibecbarcelona.eu.ORCID 0000-0002-3010-1609
Jožef Stefan Institute · SIInstitute for Bioengineering of Catalonia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Designing useful functionalities in clinically validated, old antibiotics holds promise to provide the most economical solution for the global lack of effective antibiotics, as undoubtedly a serious health threat. Here we show that using the surface chemistry of the cyclodextrin (βCD) cycle and arginine (arg) as a linker, provides more stable ternary antibiotic complex (βCD-arg-cpx). In contrast to classical less stable inclusion complexes, which only modify antibiotic solubility, here-presented ternary complex is more stable and controls drug release. The components of the complex intensify interactions with bacterial membranes and increase the drug's availability inside bacterial cells, thereby improving its antimicrobial efficacy and safety profile. Multifunctional antibiotics, formulated as drug delivery systems per se, that take the drug to the site of action, maximize its efficacy, and provide optical detectability are envisaged as the future in fighting against infections. Their role as a tool against multiresistant strains remains as interesting challenge open for further research.

Indexed as

beta-CyclodextrinsCyclodextrinsAnti-Bacterial AgentsArginineCiprofloxacinAnti-Bacterial AgentsArgininebeta-CyclodextrinsCiprofloxacinCyclodextrins

Identifiers

PMID36371541
PMCPMC9653501
OpenAlexW4308808793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.